GlassScriptPhysician profile
Ajay S Patel
NPI 1881693810
$9,028.18
in general payments reported to CMS, 2019-2025
39 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $992 · 2021: $1,411 · 2022: $1,267 · 2023: $1,186 · 2024: $1,296 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,927.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,325.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $798.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $714.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $648.65 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $485.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $468.77 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $435.18 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $412.32 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.97 | 2019-2024 | Jardiance, Ofev |
| Exact Sciences Corporation | $396.58 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $392.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $320.23 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $264.14 | 2020-2023 | |
| Intra-Sana Laboratories | $222.09 | 2021-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $186.66 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.